Format
Sort by
Items per page

Send to

Choose Destination

Best matches for glutamate schizophrenia:

Search results

Items: 1 to 20 of 3721

1.

The Role of Metabotropic Glutamate Receptors in Social Behavior in Rodents.

Zoicas I, Kornhuber J.

Int J Mol Sci. 2019 Mar 20;20(6). pii: E1412. doi: 10.3390/ijms20061412. Review.

PMID:
30897826
2.

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia.

Nicoletti F, Orlando R, Di Menna L, Cannella M, Notartomaso S, Mascio G, Iacovelli L, Matrisciano F, Fazio F, Caraci F, Copani A, Battaglia G, Bruno V.

Front Psychiatry. 2019 Feb 14;10:49. doi: 10.3389/fpsyt.2019.00049. eCollection 2019. Review.

3.

Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.

Girgis RR, Baker S, Mao X, Gil R, Javitt DC, Kantrowitz JT, Gu M, Spielman DM, Ojeil N, Xu X, Abi-Dargham A, Shungu DC, Kegeles LS.

Psychiatry Res. 2019 Mar 12;275:78-85. doi: 10.1016/j.psychres.2019.03.018. [Epub ahead of print]

PMID:
30884334
4.

Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress.

Lin CH, Lane HY.

Front Psychiatry. 2019 Feb 27;10:93. doi: 10.3389/fpsyt.2019.00093. eCollection 2019. Review.

5.

Neuronal deletion of Pten results in cerebellar motor learning dysfunction and alterations in intracellular signaling.

Nolan SO, Jefferson TS, Reynolds CD, Smith GD, Holley AJ, Hodges SL, Lugo JN.

CNS Neurol Disord Drug Targets. 2019 Mar 12. doi: 10.2174/1871527318666190312122753. [Epub ahead of print]

PMID:
30864513
6.

30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study.

Vanover K, Glass S, Kozauer S, Saillard J, Sanchez J, Weingart M, Mates S, Satlin A, Davis R.

CNS Spectr. 2019 Feb;24(1):190-191. doi: 10.1017/S1092852919000245.

PMID:
30859959
7.

Genetic variability of glutamate reuptake: Effect on white matter integrity and working memory in schizophrenia.

Mazza E, Spangaro M, Poletti S, Cavallaro R, Benedetti F.

Schizophr Res. 2019 Mar 8. pii: S0920-9964(19)30086-6. doi: 10.1016/j.schres.2019.03.004. [Epub ahead of print] No abstract available.

PMID:
30857874
8.

A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.

Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman J, Krystal JH, Corlett PR.

Neuroimage Clin. 2019 Feb 28;22:101739. doi: 10.1016/j.nicl.2019.101739. [Epub ahead of print]

9.

The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.

Pajarillo E, Rizor A, Lee J, Aschner M, Lee E.

Neuropharmacology. 2019 Mar 6. pii: S0028-3908(19)30080-2. doi: 10.1016/j.neuropharm.2019.03.002. [Epub ahead of print] Review.

PMID:
30851309
10.

Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.

Curto M, Lionetto L, Fazio F, Corigliano V, Comparelli A, Ferracuti S, Simmaco M, Nicoletti F, Baldessarini RJ.

Schizophr Res. 2019 Mar 2. pii: S0920-9964(19)30080-5. doi: 10.1016/j.schres.2019.02.020. [Epub ahead of print] No abstract available.

PMID:
30837204
11.

Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease.

Ward KR, Featherstone RE, Naschek MJ, Melnychenko O, Banerjee A, Yi J, Gifford RL, Borgmann-Winter KE, Salter MW, Hahn CG, Siegel SJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Feb 28. pii: S0278-5846(18)30865-0. doi: 10.1016/j.pnpbp.2019.02.017. [Epub ahead of print]

PMID:
30826459
12.

Mechanisms underlying the synaptic trafficking of the glutamate delta receptor GluD1.

Tao W, Ma C, Bemben MA, Li KH, Burlingame AL, Zhang M, Nicoll RA.

Mol Psychiatry. 2019 Mar 1. doi: 10.1038/s41380-019-0378-4. [Epub ahead of print]

PMID:
30824864
13.

Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.

Stansley BJ, Conn PJ.

Trends Pharmacol Sci. 2019 Feb 26. pii: S0165-6147(19)30037-9. doi: 10.1016/j.tips.2019.02.006. [Epub ahead of print] Review.

PMID:
30824180
14.

Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications.

Pillinger T, Rogdaki M, McCutcheon RA, Hathway P, Egerton A, Howes OD.

Psychopharmacology (Berl). 2019 Feb 28. doi: 10.1007/s00213-019-5188-5. [Epub ahead of print]

PMID:
30820633
15.

The Effects of Acupuncture on Glutamatergic Neurotransmission in Depression, Anxiety, Schizophrenia, and Alzheimer's Disease: A Review of the Literature.

Tu CH, MacDonald I, Chen YH.

Front Psychiatry. 2019 Feb 12;10:14. doi: 10.3389/fpsyt.2019.00014. eCollection 2019. Review.

16.

Serotonin and glutamate interactions in preclinical schizophrenia models.

Shah UH, González-Maeso J.

ACS Chem Neurosci. 2019 Feb 26. doi: 10.1021/acschemneuro.9b00044. [Epub ahead of print]

PMID:
30807107
17.

D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?

MacKay MB, Kravtsenyuk M, Thomas R, Mitchell ND, Dursun SM, Baker GB.

Front Psychiatry. 2019 Feb 6;10:25. doi: 10.3389/fpsyt.2019.00025. eCollection 2019. Review.

18.

Modular Functional-Metabolic Coupling Alterations of Frontoparietal Network in Schizophrenia Patients.

Xiang Q, Xu J, Wang Y, Chen T, Wang J, Zhuo K, Guo X, Zeljic K, Li W, Sun Y, Wang Z, Li Y, Liu D.

Front Neurosci. 2019 Feb 6;13:40. doi: 10.3389/fnins.2019.00040. eCollection 2019.

19.

Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc<sup/>.

Okada M, Fukuyama K, Kawano Y, Shiroyama T, Ueda Y.

Pharmacol Res Perspect. 2019 Feb;7(1):e00457. doi: 10.1002/prp2.457.

20.

The CNTNAP2-CASK complex modulates GluA1 subcellular distribution in interneurons.

Gao R, Zaccard CR, Shapiro LP, Dionisio LE, Martin-de-Saavedra MD, Piguel NH, Pratt CP, Horan KE, Penzes P.

Neurosci Lett. 2019 Feb 16;701:92-99. doi: 10.1016/j.neulet.2019.02.025. [Epub ahead of print]

PMID:
30779956

Supplemental Content

Loading ...
Support Center